Navigation Links
Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
Date:10/14/2008

REINACH, Switzerland, October 14 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that the agency's Anti-Infective Drugs Advisory Committee will discuss the New Drug Application (NDA) for intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI) during its meeting on 18-20 November 2008. An Advisory Committee can be requested by FDA as part of the review process of an NDA or supplemental NDA.

Iclaprim is a hospital antibiotic drug candidate with potent bactericidal (killing) activity against MRSA and an extended range of important pathogens. To date, Arpida has filed marketing applications for intravenous iclaprim in the treatment of complicated Skin and Skin Structure Infections in the U.S.A., Canada and the European Union.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "We are delighted to have an opportunity to present iclaprim to leading experts in the anti-infective field and to discuss important features of our NDA with the Advisory Committee."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008. The FDA has defined that the Prescription
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
2. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
3. Arpida Provides Further Comments on the Pivotal Phase III Trials
4. Arpida Invited to Present Data on Iclaprim at Scientific Conference
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
9. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
10. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
11. Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... 2, 2011 The Center for Radiation Therapy of ... patients in the Los Angeles area, has been awarded ... the result of a recent review by the American ... Radiation Oncology (ASTRO). Radiation oncology (radiation ...
... Va., March 2, 2011 Insmed Incorporated (Nasdaq: ... the one-for-10 reverse stock split of Insmed,s Common Stock ... 2, 2011, after the State Corporation Commission of the ... of Incorporation to effect the reverse stock split.  The ...
Cached Medicine Technology:The Center for Radiation Therapy of Beverly Hills Earns ACR-ASTRO Accreditation 2The Center for Radiation Therapy of Beverly Hills Earns ACR-ASTRO Accreditation 3One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective 2
(Date:12/20/2014)... News) -- The holidays can be anything but joyous ... trees, scented candles and other allergy triggers. "The ... have been packed away in dank basements or dusty ... patients," Dr. Rachna Shah, an affiliate faculty member at ... Loyola news release. Shah, who is also an ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The Doctor’s Office ... for the better part of a decade. They’ve treated ... a better, faster healthcare alternative to the Paramus ... announce three new additions to their staff of top-notch board ... Jill Zeiger MD. These new doctors will work ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The aftermath of ... quite a stir, not only in Hollywood, but worldwide. ... 18th , the ripples of that attack are starting a ... jobs at risk. But they are not the only ... could be in for some embarrassing times ahead, agents and ...
(Date:12/20/2014)... Developers of FCPX 3rd Party ... for Final Cut Pro X entitled TranSlice Volume 5 ... users to create hand drawn text animations without having ... of Pixel Film Studios. “TranSlice Volume 5 was professionally ... easy to use interface.” , TranSlice Volume 5 from ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... (fight against inflammation) that are 10, 000 times more ... nimusulide and aspirin have been developed and patented by ... Medical Sciences (AIIMS), situated in New Delhi, India, have ... about 10,000 times better than the commonly used pain ...
... is threatening to cause a major upheaval to the ... spread, according to the Coordinating Minister// for People’s Welfare, ... expressed fears on the dwindling poultry industry and a ... to the pandemic. ,The consequences would be ...
... the magnets that are sold in the market does not ... problems//. Magnet that are advertised over the net and sold ... value. ,Magnets are sought after by the successful ... it is all bogus. The research was done by ...
... not aware about dugs and its effect till 1980. But ... is a lot of information available from varied sources// such ... ,The information that is available in these formats has to ... made accessible. This was done by Dr. David Wishart, faculty ...
... symposium on Stem cell Research and Therapy was conducted ... was organized by LifeCell//, a pioneer in stem cell ... Research Institute, one of the reputed medical institutions in ... hematologist, CMC, Vellore, headed the symposium. Following a small ...
... Woodruff (R) said he had filed a bill (HB 1096) that ... would endanger the life or health of the mother. ... a Class C felony, carrying a two- to eight-year prison sentence. ... a state must pass a law and then appeal it to ...
Cached Medicine News:Health News:Does Magnet Therapy Posses Healing Powers? 2Health News:Drug Database Goes On Air 2Health News:Stem Cell Research - Changing Wishes to Possibilities and Possibilities to Reality 2
... The TL-100 uses technology that takes ... by automatically detecting and reading them. It ... recording the results, mark lenses as you ... contact lenses. Easy to use, the TL-100 ...
... The Kowa RC-XV3 camera is ... The automatic exposure system, ... sensitivity, the 2.5~300ws watt indication ... handling are the basic features ...
FF 450plus fundus camera for 35mm photography. Upgradeable basic instrument for brilliant image quality....
The new TRC-NW6 non-mydriatic retinal camera is the ideal instrument for the growing market in telemedicine and diabetic screening....
Medicine Products: